Neurilemmoma
A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)
Subtype terms (1)
More specific conditions that are subtypes of Neurilemmoma in the MeSH hierarchy.
- Neuroma, Acoustic
21 drugs (14 approved, 7 experimental)
Drugs by status
Phase 2 trials (3)
Phase 1 trials (1)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 2 Indications (26)
- Takeda
- AstraZeneca
- Genentech
- Pfizer
- Novartis
- Auris Medical
- Betta Pharmaceuticals Co.,Ltd.
- GlaxoSmithKline
- Simcere Pharmaceutical Co., Ltd
- National Cancer Institute (NCI)
- Beijing Tiantan Hospital
- Burzynski Research Institute
- Harvard University
- Johns Hopkins University
- New York University
- Northwestern University
- University of Toronto
- Mayo Clinic
- Capital Medical University
- University of California, Los Angeles
- University of Cincinnati
- Department of Defense
- University of Alabama, Birmingham
- University of Paris
- The Children's Tumor Foundation
- Memorial Sloan-Kettering Cancer Center
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (3)